Sp1177
HOW TO RECOGNIZE SEXUALLY TRANSMITTED INFECTIONS OF THE ANORECTUM: IT MIGHT NOT BE IBD!
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners. Two of the sessions will provide vital clinical updates for all clinicians on anorectal disease and provider affirming care for the transgender community. Two other sessions will share strategies for creating a safe and effective practice and learning environment for sexual and gender minority patients, providers and learners. Practice and divisional leaders as well as clinicians will benefit from this session.
LGBTQ+ health care providers and patients are a growing and visible part of GI and liver practice. This session spotlights clinicians who are addressing the health needs for the LGBTQ+ population of patients, providers and learners. Two of the sessions will provide vital clinical updates for all clinicians on anorectal disease and provider affirming care for the transgender community. Two other sessions will share strategies for creating a safe and effective practice and learning environment for sexual and gender minority patients, providers and learners. Practice and divisional leaders as well as clinicians will benefit from this session.
Presenter
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
